Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia	B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, acute biphenotypic leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease	Active, not recruiting	Phase 1	2026-08-20		NCT02879695

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Dana-Farber Cancer Institute	Boston	United States	626
Huntsman Cancer Institute/University of Utah	Salt Lake City	United States	249
Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore	United States	238
Ohio State University Comprehensive Cancer Center	Columbus	United States	548
University of Kentucky/Markey Cancer Center	Lexington	United States	240
UPMC Hillman Cancer Center	Pittsburgh	United States	330
Yale University	New Haven	United States	352